PHVS
Pharvaris BVNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.96B
P/E Ratio
—
EPS
$-3.54
Beta
-2.33
52W High
$31.14
52W Low
$14.59
50-Day MA
$27.68
200-Day MA
$25.02
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Pharvaris BV
Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies. The company is headquartered in Leiden, the Netherlands.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-169.63M |
| Operating Margin | 0.00% |
| Return on Equity | -65.20% |
| Return on Assets | -35.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.88 |
| Price-to-Book | 6.07 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -1.38 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $65.41M |
| Float | $35.18M |
| % Insiders | 5.16% |
| % Institutions | 90.64% |
Historical Volatility
HV 10-Day
75.39%
HV 20-Day
57.42%
HV 30-Day
52.50%
HV 60-Day
47.73%
HV Rank
40.9%
Volatility is currently expanding
Analyst Ratings
Consensus ($46.54 target)
3
Strong Buy8
Buy1
HoldMore HEALTHCARE Stocks
Data last updated: 5/5/2026